Free provider profile
MICHAEL BANOV, MD
NPI 1881771004
Individual
Psychiatry & Neurology, Psychiatry
Active registration
Save to rep workspaceNPI registry Registry record
Source: CMS NPPES registry, updated continuously. This record was last updated 2026-03-23.
1012 COGGINS PL NE, MARIETTA, GA, 30060
770-422-2009
7 practice locations listed
Enumerated 2006-11-01
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 7 practice locations listed — multi-site footprint.
- — 1 payer identifiers on file — enrolled with payers.
- — Record updated within the last year.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
5,113
Medicare patients
333
Part D drug cost
$1,148,473
Brand-name share
10%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Ingrezza (Valbenazine Tosylate) | 28 | $227,807 |
| Austedo Xr (Deutetrabenazine) | 15 | $174,988 |
| Austedo (Deutetrabenazine) | 18 | $101,197 |
| Caplyta (Lumateperone Tosylate) | 40 | $67,986 |
| Invega Sustenna (Paliperidone Palmitate) | 20 | $67,383 |
| Auvelity (Dextromethorphan Hbr/Bupropion) | 54 | $61,349 |
| Rexulti (Brexpiprazole) | 13 | $58,182 |
| Fanapt (Iloperidone) | 29 | $39,575 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Spravato (esketamine) Medicare billing
Source: CMS Medicare Part B fee-for-service, HCPCS G2082/G2083.
2024242 sessions · 16 patients · $205,825
2023153 sessions · 12 patients · $140,679
Full Spravato label-compliance detail — sessions per patient against the FDA label, risk flags and year-over-year trend.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.